Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.

Vitamin D may help prevent advanced cancer in older adults

Pearl Toh
09 Jul 2020

Vitamin D supplementation can reduce the incidence of advanced cancer among older adults, in particular those with a normal BMI but not those who are overweight or obese, suggests the large VITAL* randomized study presented during the ASCO 2020 Meeting.

“Our results suggest a cost-effective, safe, and accessible vitamin as a potential new prevention strategy for advanced cancer,” said lead author Dr Paulette Chandler from Brigham and Women’s Hospital, Harvard Medical School in Boston, Massachusetts, US.

“To date, no established supplement has been associated with a reduction in incidence of advanced cancer,” she added. “Even if vitamin D effects were modest, vitamin D supplementation at the studied levels are much less toxic and lower in cost than many current cancer therapies.”

“These results may have a wide-reaching, global impact, regardless of a patient’s socioeconomic status or a country’s resources,” highlighted Chandler.

Participants who received vitamin D supplementation had 17 percent lower risk of developing advanced (metastatic and fatal) cancer of any type than those on placebo (hazard ratio [HR], 0.83; 95 percent confidence interval [CI], 0.69–0.99; p=0.036). [ASCO 2020, abstract 1510]

When the analysis was stratified based on BMI, the reduction in advance cancer risk was particularly profound in participants with a normal BMI (BMI <25 kg/m2; HR, 0.62; 95 percent CI, 0.45-0.86), while those who were obese (BMI  ≥30 kg/m2) saw no protective benefit from vitamin D supplementation (HR, 1.05; 95 percent CI, 0.74-1.49; p-interaction=0.03).

In comparison, participants who were overweight (BMI ≥25 to <30 kg/m2) saw an 11 percent reduction in advance cancer risk with vitamin D vs placebo (HR, 0.89; 95 percent CI, 0.68-1.17).

“Individuals with a normal BMI derived the most benefit,” reported Chandler.

VITAL is a placebo-controlled trial with a 2x2 factorial design: participants were randomized 1:1 to receive vitamin D3 (cholecalciferol; 2,000 IU/day) supplementation or placebo; and then each arm was rerandomized 1:1 to 1 g daily supplements of marine omega-3 fatty acids or placebo for a median duration of 5.3 years. Participants were 25,871 healthy men (≥50 years) and women (≥55 years) who were free of cardiovascular disease and cancer at baseline. A total of 1,617 patients developed invasive cancer during follow-up. 

There was no significant difference in advanced cancer rates among patients receiving omega-3 supplementation vs those on placebo (HR, 0.97, 95 percent CI, 0.81-1.15; p=0.72).

Explaining on the potential reason why obese individuals did not derive a protective benefit from vitamin D supplementation, Chandler suggested that the bioactivity of vitamin D might be decreased in these individuals due to volumetric dilution.

“Whether overweight/obese persons require higher doses to derive cancer benefit, analogous to body size differences in aspirin dosage requirements, should be evaluated,” she said.

 

*VITAL: The VITamin D and omegA-3 triaL

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Doctor - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Elaine Soliven, 4 days ago

Switching from efavirenz/emtricitabine/tenofovir disoproxil fumarate (EFV/FTC/TDF) to the new bictegravir/ emtricitabine/tenofovir alafenamide (BIC/FTC/TAF) regimen maintained high rates of virological suppression in adults who are living with HIV*, according to a study presented at AIDS 2020.

01 Aug 2020
Supplementation with probiotics may have positive effects in patients with type 2 diabetes mellitus (T2DM), reports a recent meta-analysis.
Stephen Padilla, 4 days ago
Pre-exposure prophylaxis (PrEP) containing either long-acting injectable cabotegravir (CAB) or tenofovir/emtricitabine (TDF/FTC) is safe and effective for transgender women (TGW) and cisgender men who have sex with men (MSM), but CAB results in a much lower HIV incidence compared to TDF/FTC, results of the HIV Prevention Trials Network (HPTN) 083 have shown.
Jairia Dela Cruz, 3 days ago
Monthly prophylaxis with the fixed-dose combination of naphthoquine-azithromycin (NQAZ) is well tolerated and confers significant protection against infection with Plasmodium parasites among individuals residing in malaria-endemic areas in Southeast Asia, as shown in the results of a phase III trial.